Gut bacteria treatment to improve CAR-T therapy for lymphoma and myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether a special mix of gut bacteria can make CAR-T cell therapy work better for people with large B-cell lymphoma or multiple myeloma. You will take capsules of these bacteria before and during CAR-T treatment to see if it helps your body respond to the therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with large B-cell lymphoma or multiple myeloma and are scheduled to receive a commercial CAR-T therapy.
- You are at least 18 years old.
- You are generally able to perform daily activities (ECOG performance status 2 or better).
- You can take capsules by mouth (no swallowing difficulties).
- You do not have active inflammatory bowel disease, intestinal bleeding, or other serious gut conditions.
- You are not taking other experimental treatments during this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR-T cells that are specially designed to find and attack your cancer cells. It is for people with certain blood cancers that have not improved with standard treatments, and it may give you another option when others have not worked.
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
This study tests whether a fecal transplant (transferring healthy gut bacteria) can improve outcomes for people with certain lymphomas who have taken strong antibiotics and are about to get CAR T-cell therapy (Yescarta). The goal is to see if rebuilding gut bacteria helps the treatment work better.
This trial tests whether giving a fecal transplant (a stool enema from a healthy donor) can improve the response to CAR T-cell therapy in people with B-cell lymphoma. It may help by restoring healthy gut bacteria that are often wiped out by strong antibiotics.
This trial compares two ways of giving antibiotics to people receiving CAR-T cell therapy for lymphoma or myeloma. It aims to find out whether a more limited antibiotic approach is just as safe and effective as the standard one, possibly reducing side effects.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.